BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Russell FM, Carapetis JR, Burton RL, Lin J, Licciardi PV, Balloch A, Tikoduadua L, Waqatakirewa L, Cheung YB, Tang ML. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine. 2011;29:535-544. [PMID: 21044669 DOI: 10.1016/j.vaccine.2010.10.046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 van den Biggelaar AHJ, Pomat WS, Masiria G, Wana S, Nivio B, Francis J, Ford R, Passey M, Kirkham LA, Jacoby P, Lehmann D, Richmond P; 10v13v PCV Trial Team. Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children. Vaccines (Basel) 2019;7:E17. [PMID: 30720721 DOI: 10.3390/vaccines7010017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Lehmann D, Kirarock W, van den Biggelaar AHJ, Passey M, Jacoby P, Saleu G, Masiria G, Nivio B, Greenhill A, Orami T, Francis J, Ford R, Kirkham LA, Solomon V, Richmond PC, Pomat WS; 10v13v PCV trial team. Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea. Pneumonia (Nathan) 2017;9:20. [PMID: 29299402 DOI: 10.1186/s41479-017-0044-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dunne EM, Tikkanen L, Balloch A, Gould K, Yoannes M, Phuanukoonnon S, Licciardi PV, Russell FM, Mulholland EK, Satzke C, Hinds J. Characterization of 19A-like 19F pneumococcal isolates from Papua New Guinea and Fiji. New Microbes New Infect 2015;7:86-8. [PMID: 26339490 DOI: 10.1016/j.nmni.2015.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Ameratunga R, Allan C, Woon ST. Defining Common Variable Immunodeficiency Disorders in 2020. Immunol Allergy Clin North Am 2020;40:403-20. [PMID: 32654689 DOI: 10.1016/j.iac.2020.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
5 Fritzell B, Fletcher MA. Pneumococcal polysaccharide–protein (CRM 197 ) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Expert Review of Vaccines 2014;10:263-90. [DOI: 10.1586/erv.11.11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
6 Bjarnarson SP, Benonisson H, Del Giudice G, Jonsdottir I. Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness. PLoS One 2013;8:e72588. [PMID: 24069152 DOI: 10.1371/journal.pone.0072588] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
7 Burton RL, Geno KA, Saad JS, Nahm MH. Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide. J Clin Microbiol 2016;54:967-71. [PMID: 26818670 DOI: 10.1128/JCM.03194-15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
8 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr 2016; 5(3): 311-318 [PMID: 27610348 DOI: 10.5409/wjcp.v5.i3.311] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK. Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine 2015;33:5042-50. [DOI: 10.1016/j.vaccine.2015.07.102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
10 Tashani M, Rashid H, Mulholland K, Booy R. Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children. Pneumonia (Nathan) 2016;8:16. [PMID: 28702295 DOI: 10.1186/s41479-016-0016-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Russell FM, Balloch A, Licciardi PV, Carapetis JR, Tikoduadua L, Waqatakirewa L, Cheung YB, Mulholland EK, Tang ML. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 2011;29:4499-506. [PMID: 21539882 DOI: 10.1016/j.vaccine.2011.04.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
12 Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011;10:307-22. [PMID: 21434799 DOI: 10.1586/erv.11.8] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 10.4] [Reference Citation Analysis]
13 Licciardi PV, Balloch A, Russell FM, Burton RL, Lin J, Nahm MH, Mulholland EK, Tang ML. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012;129:794-800.e2. [PMID: 22305678 DOI: 10.1016/j.jaci.2011.11.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
14 Knuf M, Pankow-culot H, Grunert D, Rapp M, Panzer F, Köllges R, Fanic A, Habib A, Borys D, Dieussaert I, Schuerman L. Induction of Immunologic Memory Following Primary Vaccination With the 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Infants. Pediatric Infectious Disease Journal 2012;31:e31-6. [DOI: 10.1097/inf.0b013e3182323ac2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
15 Crawford NW, Balloch A, Tikkanen L, Merchinaud F, Downie P, Buttery JP. Pneumococcal conjugate vaccine administration during therapy for pediatric leukemia. Pediatr Infect Dis J 2015;34:e9-15. [PMID: 25101761 DOI: 10.1097/INF.0000000000000502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
16 Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczyńska M, Navarro M, Scherpbier HJ, Heath PT; Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group., PENTA Steering Committee., Children's HIV Association (CHIVA). Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012;13:333-6; e1-14. [PMID: 22296225 DOI: 10.1111/j.1468-1293.2011.00982.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
17 Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174:203-211. [PMID: 23859429 DOI: 10.1111/cei.12178] [Cited by in Crossref: 29] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
18 Thisyakorn U, Chokephaibulkit K, Kosalaraksa P, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine. Hum Vaccin Immunother 2014;10:1859-65. [PMID: 25424793 DOI: 10.4161/hv.28642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Sucher AJ, Chahine EB, Nelson M, Sucher BJ. Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine. Ann Pharmacother 2011;45:1516-24. [DOI: 10.1345/aph.1q347] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
20 Jackowska T, Pluta J. Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens. Arch Med Sci 2012;8:542-8. [PMID: 22852013 DOI: 10.5114/aoms.2012.29410] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C, Krause V, McIntyre P. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine. 2015;33:6666-6674. [PMID: 26519550 DOI: 10.1016/j.vaccine.2015.10.089] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
22 Ameratunga R, Woon ST. Perspective: Evolving Concepts in the Diagnosis and Understanding of Common Variable Immunodeficiency Disorders (CVID). Clin Rev Allergy Immunol 2020;59:109-21. [PMID: 31720921 DOI: 10.1007/s12016-019-08765-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
23 Licciardi PV, Balloch A, Russell FM, Nahm MH, Mulholland K, Tang ML. Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function. Nat Rev Drug Discov 2011;10:393. [PMID: 21532568 DOI: 10.1038/nrd3012-c1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]